Oku N - Search Results

1

Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.

Fukuta T, Asai T, Yanagida Y, Namba M, Koide H, Shimizu K, Oku N. Fukuta T, et al. Among authors: oku n. FASEB J. 2017 May;31(5):1879-1890. doi: 10.1096/fj.201601209R. Epub 2017 Jan 12. FASEB J. 2017. PMID: 28082354

-Fukuta, T., Asai, T., Yanagida, Y., Namba, M., Koide, H., Shimizu, K., Oku, N. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke....

-Fukuta, T., Asai, T., Yanagida, Y., Namba, M., Koide, H., Shimizu, K., Oku, N. Combination therapy with liposomal neuroprotec …

2

Antitumor activity of 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization.

Asai T, Kurohane K, Shuto S, Awano H, Matsuda A, Tsukada H, Namba Y, Okada S, Oku N. Asai T, et al. Among authors: oku n. Biol Pharm Bull. 1998 Jul;21(7):766-71. doi: 10.1248/bpb.21.766. Biol Pharm Bull. 1998. PMID: 9703265 Free article.

3

Suppression of GD1alpha ganglioside-mediated tumor metastasis by liposomalized WHW-peptide.

Takikawa M, Kikkawa H, Asai T, Yamaguchi N, Ishikawa D, Tanaka M, Ogino K, Taki T, Oku N. Takikawa M, et al. Among authors: oku n. FEBS Lett. 2000 Jan 28;466(2-3):381-4. doi: 10.1016/s0014-5793(00)01110-8. FEBS Lett. 2000. PMID: 10682865 Free article.

4

Evaluation of drug targeting strategies and liposomal trafficking.

Oku N, Tokudome Y, Asai T, Tsukada H. Oku N, et al. Curr Pharm Des. 2000 Nov;6(16):1669-91. doi: 10.2174/1381612003398816. Curr Pharm Des. 2000. PMID: 10974160 Review. No abstract available.

5

Targeting and anti-tumor efficacy of liposomal 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma.

Asai T, Shuto S, Matsuda A, Kakiuchi T, Ohba H, Tsukada H, Oku N. Asai T, et al. Among authors: oku n. Cancer Lett. 2001 Jan 10;162(1):49-56. doi: 10.1016/s0304-3835(00)00633-9. Cancer Lett. 2001. PMID: 11121862

6

Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels.

Asai T, Nagatsuka M, Kuromi K, Yamakawa S, Kurohane K, Ogino K, Tanaka M, Taki T, Oku N. Asai T, et al. Among authors: oku n. FEBS Lett. 2002 Jan 16;510(3):206-10. doi: 10.1016/s0014-5793(01)03265-3. FEBS Lett. 2002. PMID: 11801255 Free article.

7

Anti-neovascular therapy using novel peptides homing to angiogenic vessels.

Oku N, Asai T, Watanabe K, Kuromi K, Nagatsuka M, Kurohane K, Kikkawa H, Ogino K, Tanaka M, Ishikawa D, Tsukada H, Momose M, Nakayama J, Taki T. Oku N, et al. Oncogene. 2002 Apr 18;21(17):2662-9. doi: 10.1038/sj.onc.1205347. Oncogene. 2002. PMID: 11965539

8

Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.

Asai T, Shimizu K, Kondo M, Kuromi K, Watanabe K, Ogino K, Taki T, Shuto S, Matsuda A, Oku N. Asai T, et al. Among authors: oku n. FEBS Lett. 2002 Jun 5;520(1-3):167-70. doi: 10.1016/s0014-5793(02)02821-1. FEBS Lett. 2002. PMID: 12044891 Free article.

9

Potential usage of liposomal 4beta-aminoalkyl-4'-O-demethyl-4-desoxypodophyllotoxin (TOP-53) for cancer chemotherapy.

Shimizu K, Takada M, Asai T, Irimura K, Baba K, Oku N. Shimizu K, et al. Among authors: oku n. Biol Pharm Bull. 2002 Jun;25(6):783-6. doi: 10.1248/bpb.25.783. Biol Pharm Bull. 2002. PMID: 12081147 Free article.

10

Cancer antineovascular therapy.

Oku N, Asai T, Kurohane K, Watanabe K, Kuromi K, Namba Y, Ogino K, Taki T. Oku N, et al. Cell Mol Biol Lett. 2002;7(2):247-8. Cell Mol Biol Lett. 2002. PMID: 12097936 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

594 results

Search Page

Filters